Skip to main content

Table 1 Clinical profiles of aspirin intolerance asthma and control subjects

From: Association of CACNG6 polymorphisms with aspirin-intolerance asthmatics in a Korean population

Clinical profile AIA ATA
Number of subjects (n) 102 429
Age [year, mean (range)] 42.76 (18.66-72.73)* 47.30 (15.40-77.88)
Sex (n, male/female) 37/65 147/282
Smoker (current smoker/exsmoker) (%) 21.36 (13.59/7.77)* 30.07 (12.35/17.72)
Height [cm, mean (range)] 161.70 ± 9.91 160.42 ± 8.39
Weight (kg) 61.64 ± 10.39 63.40 ± 10.97
Body mass index (kg/m2) 23.56 ± 3.37* 24.58 ± 3.39
% decline of FEV1 by aspirin provocation 33.59 ± 13.42** 3.54 ± 4.85
Blood eosinophil (%) 6.65 ± 5.78 6.03 ± 5.92
FEV1 (% predicted) 85.10 ± 16.41* 91.66 ± 16.87
PC20 methacholine (mg/ml) 4.26 ± 7.62* 6.91 ± 8.90
Total IgE (IU/ml) 415.74 ± 714.70 361.00 ± 607.56
Positive rate of skin test (%) 48.04 57.81
  1. Age indicates a first medical examination. AIA, aspirin-intolerant asthma; ATA, aspirin-tolerant asthma.
  2. *P < 0.05; **P < 0.0001 compared to ATA control.